App-Quantinova.ai

Impact of Tricuspid Regurgitation and Tricuspid Annulus Dilation on Mortality After Transcatheter Aortic Valve Replacement

Oumhanie Toubal - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Tricuspid regurgitation

N/A

Determinants of Rehospitalization After Cardiac Surgery in Prolonged ICU Length of Stay Survivors

Rakesh C Arora - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

How Common is New Onset Atrial Fibrillation in Single Chamber ICD Patients? Sub-analysis From the PainFree SST Study

Angelo Auricchio - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis

Vincent Probst - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ventricular arrhythmias

N/A

Prognostic Value of Baseline BNP and NT-ProBNP and its Interaction with Spironolactone in Patients with Heart Failure and Preserved Ejection Fraction in the TOPCAT Trial

Scott D Solomon - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Spironolactone

Low Operative Mortality Achieved with Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction

Joseph A Dearani - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertrophic cardiomyopathy

N/A

Prevention of Progressive Worsening of Heart Failure Over Time with the Angiotensin-receptor Neprilysin Inhibitor Sacubitril/valsartan (lcz696)

Pardeep Jhund - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Sacubitril/valsartan

Anemia in Heart Failure with Preserved Ejection Fraction: Insights From the TOPCAT trial

Christopher T Kenwood - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

Spironolactone

Left Ventricular Remodeling and Function Following Aortic Valve Replacement for Low-flow, Low-gradient Aortic Stenosis with Preserved Ejection Fraction-results From the TOPAS Study

Marie-Annick Clavel - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Aortic stenosis

N/A

Impact of Pulmonary Valve Replacement on Right Ventricular Myocardial Deformation in Repaired Tetralogy of Fallot

Luc Mertens - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary regurgitation

N/A

Pulmonary Artery Calcification: A New Threat in Pulmonary Arterial Hypertension

Gregoire Ruffenach - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Role of Wnts and Secreted Frizzled-related Protein-1 in Atrial Fibroblast Pathophysiology During Atrial Fibrotic Remodeling

Kristin Dawson - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

DE-074

Myocardial Recovery in Peripartum Cardiomyopathy: Effect of the GNB3 C825T Polymorphism in the Multicenter IPAC study

Julie Damp - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Peripartum cardiomyopathy

N/A

Control of Fibroblast Function by Adrenergic/EPAC System and Potential Role in Atrial Remodeling

Mona Aflaki - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Norepinephrine bitartrate

Norepinephrine Levels are Associated with the Magnitude of Vasoconstriction During Mental Stress

Nino Isakadze - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronary Artery Disease

Norepinephrine bitartrate

Electrophysiological Substrate and Risk of Mortality in Incident Hemodialysis Patients: Predictors of Arrhythmic and Cardiovascular Risk in End-stage Renal Disease (PACE) Study

Andrew Oehler - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Left ventricular hypertrophy

N/A

Prognostic Value of Subjective and Objective Findings of Ischemia in Patients with Heart Failure

Jack V Tu - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Prolonged QRS Duration Predicts Outcomes in Heart Failure with Preserved Ejection Fraction

Brian L Claggett - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

Spironolactone

Identifying Patients with Acute Heart Failure Who Require a Critical Care Admission: ASCEND-HF Insights

Cynthia M Westerhout - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Ventricular arrhythmias

Angiotensin II

Apical Sparing Longitudinal Strain Pattern with Cardiac MRI Correlates with LGE Distribution in Cardiac Amyloidosis

Lynne K Williams - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Filters

28841 Abstracts